Filters

Search for: [Abstract = "The theories formulated to explain atherogenesis have been evolving from vessel wall lipid accumulation to endothelial dysfunction with vascular wall remodelling. The progress in basic and experimental science have shown that inflammatory and immunological processes, cell and molecular machanizm can initiate atherogenesis. High frequency of cardiac and vessel disease creating on the ground of atherosclerosis caused that prevention is one of major aim of medicine. Estimating the risk of coronary artery disease and coming of clinicals incidents is the basic aim of intervention work. Markers of endothelian demage and activation inflammatory response have a prognostic value independent of clasic risk factors. Diagnostic these markers, although still limited, shought become the basic way of identification patients, that are the most danger with aterosclerosis complications. In the study tried to estimate the level of anti\-hsp60 antibody, C\-reactive protein, fibrinogen, leucocytes and anti\-Ch.p. in class IgG and IgA in group with stable coronary artery disease \(CAD\) and in group with healthy subjects. In the research comperized the level of anti\-hsp60 antibodies, C\-reactive protein, fibrinogen, leucocytes and anti\-Ch.p. in class IgG and IgA in depending on amount of vessels involved in atherosclerosis and progressing atherosclerosis according to classyfication of Canadian Cardiological Assocation. Additionally examined correlation between anti\-hsp60 antibody, seropositivity to Ch.p. infection \(the level of IgG and IgA antibodies\) and the level of C\-reactive protein, fibrinogen, leucocytes in patients with CAD and in group with healthy volunteers and also in group in CAD depending on amount of vessels involved in atherosclerosis and progressing atherosclerosis according to classyfication of Canadian Cardiological Assocation. The study group consisted of 71 patients aged 37\-53 \(47,07 ± 4,23 years\) from the 2ndDepartment of Cardiology at the Medical College of Jagiellonian University in Cracow, with stable CAD. The control group consisted of 31 healthy volunteers aged 37\-53, \(44,97 ± 5,38 years\) matched according to sex and age, non\-smokers, with normal lipid levels, blood pressure and body mass. The exclusion criteria from the study were\: an active inflammatory process hypertension diabetes mellitus obesity \(BMI<30kg\/m2\), and lipids disorders, absence of autoimmunological states and neoplasms. In all patients according to the medical history excluded active \(the last 8 weeks\) and chronic inflammatory and infective disease, autoimmunological states and neoplasm, diabetes, endocrinological disorders and liver disease. All patients had proper blood pressure values \(systolic pressure < 140mmHg, diastolic pressure < 90mmHg\), non\-smokers at least since 2 years. In this way excluded part of factors involving in research results. To confirm the diagnosis by all participants medical history, patient examination, clinical measurments, ecg, exercise ecg, coronarography were made. In examined patients percutaneous angioplasty were made \(PTCA\) and biochemical paramets were taken 6 months after succesful coronary angioplasty. 65% of patients with CAD demonstrated symptoms of CCS I a 35% CCS II according to classyfication of Canadian Cardiological Assocation. By 60% patients with CAD confirmed one vessel coronary disease and by 40% patients multi\-vessel disease. Patients were treated with standard farmacological therapy according obligatory guidlines \(aspirin, ACE\- inhibitor, beta\-blocer, statin\). The study protocol was approved by the Jagiellonian University Medical College Ethics Committee and informed consent was obtained from all participants. Venous blood samples were drawn after an overnight fast to measure the level of anti\-hsp60 antibody, high sensitive C\-reactive protein, fibrinogen, leucocytes and anti\-Ch.p. in class IgG and IgA antibodies. The level of anti\-hsp60 and anti\-Ch.p."]

Number of results: 0

No results. Change search criteria.

This page uses 'cookies'. More information